Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!

What Long-Term Growth Rate is Expected for the Onpattro Market Between 2025 and 2034?

The market size of onpattro has experienced a growth of XX (CAGR) in the recent past. Its market valuation is set to expand from $XX million in 2024 to $XX million in 2025, registering a compound annual growth rate (CAGR) of XX%. Factors such as the growing incidence of hereditary transthyretin-mediated amyloidosis, improved knowledge of rare diseases, escalated investment in research and development, increasing aging population, and elevated expenditure in healthcare have all fueled this growth over the historic period.

Expectations are high for the onpattro market, with an anticipated size expansion of XX (CAGR) in the coming years. It’s predicted to reach a worth of $XX million by 2029, reflecting a compound annual growth rate (CAGR) of XX%. The growth during this forecasted period is likely to be driven by collaborations and licensing, regulatory assistance, a rise in chronic illnesses, increasing partnerships in the biopharmaceutical arena, and a growing number of transthyretin amyloidosis cases. The period is also expected to witness trends such as an increased use of ribonucleic acid-based therapies, a surge in orphan drug designations, the integration of digital health tools, a shift towards personalized medicine, and advancements in drug delivery technology.

What Are the Primary Drivers Supporting the Growth of the Onpattro Market?

An increasing number of hereditary transthyretin-mediated amyloidosis cases is anticipated to bolster the development of the onpattro market in the future. Hereditary transthyretin-mediated amyloidosis (hATTR) is a rare genetic disease characterized by the formation of harmful deposits by mutated TTR proteins, which impacts the nerves and the heart. The surge in hereditary transthyretin-mediated amyloidosis instances can be credited to improved diagnostics, genetic testing, and increased awareness that leads to the detection of more cases. Onpattro functions by mitigating the transthyretin (TTR) gene to lower the production of amyloid proteins and thereby preventing damage to organs. For example, in February 2024, data from Verywell Health, a health information platform based in the U.S., stated that globally, hereditary transthyretin-mediated amyloidosis affects 5,500–38,500 individuals. Within the U.S., the estimate ranges from 104 to 3,847 cases of hereditary transthyretin-mediated amyloidosis with polyneuropathy, thereby underlining substantial underdiagnosis. Therefore, the escalating number of hereditary transthyretin-mediated amyloidosis cases is contributing to the expansion of the onpattro market.

Get Your Free Sample of the Global Onpattro Market Report Now!

https://www.thebusinessresearchcompany.com/sample.aspx?id=20169&type=smp

What Are the Key Firms That Are Driving Transformation in the Onpattro Market?

Major companies operating in the onpattro market include Alnylam Pharmaceuticals Inc.

What Current Trends in the Onpattro Market Should Industry Players Pay Attention To?

The primary trend in the Onpattro market leans towards increasing the drug’s indications by employing supplemental drug applications, with the main goal to gain broader market coverage and cater to a more diverse patient base. Most of the time, these supplemental drug applications are intended to widen the approved applications of a drug, possibly targeting new indications, population sets, or drug formats, thereby enhancing its therapeutic extent and market reach. For example, Alnylam Pharmaceuticals, a pharmaceutical firm based in the US, confirmed the approval of a Supplemental New Drug Application (sNDA) for ONPATTRO (patisiran) in February 2023. This medication is formulated to treat cardiomyopathy related to transthyretin amyloidosis (ATTR). ONPATTRO works as an RNA interference (RNAi) treatment aimed exclusively at the transthyretin (TTR) protein, which tends to accumulate excessively in patients suffering from ATTR amyloidosis, causing severe conditions such as cardiomyopathy. Initially, the drug was sanctioned in 2018 for treating polyneuropathy associated with hereditary ATTR amyloidosis. The current sNDA application drew its basis from the outcomes of the third-phase APOLLO-B trial which confirmed that patisiran notably enhanced the functional capability and lifestyle quality in cardiomyopathy patients, compared to a placebo.

Secure Your Global Onpattro Market Report Now for Fast and Efficient Delivery!

https://www.thebusinessresearchcompany.com/report/onpattro-global-market-report

How Are Market Segments in the Onpattro Industry Positioned for Long-Term Growth?

The onpattro market covered in this report is segmented –

1) By Clinical Indication: Hereditary Transthyretin-Mediated Amyloidosis, Wild-Type Transthyretin Amyloidosis, Other Transthyretin-Related Amyloidoses

2) By Distribution Channel: Direct Sales, Pharmacies, Online Pharmacies

3) By End User: Hospitals, Specialty Clinics, Home Healthcare Providers

What Regions Are Driving Expansion in the Onpattro Market?

North America was the largest region in the onpattro market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the onpattro market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

What Key Parameters Define the Onpattro Market’s Scope?

Onpattro (patisiran) is an FDA-approved medication used to treat hereditary transthyretin-mediated amyloidosis (hATTR), a rare genetic disorder. It works by targeting and silencing the transthyretin (TTR) gene to reduce the production of amyloid proteins that cause organ damage. Onpattro is delivered via intravenous infusion and helps manage symptoms and improve the quality of life for affected patients.

Browse Through More Similar Reports By The Business Research Company:

Neuroprosthetics Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/neuroprosthetics-global-market-report

Neuroscience Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/neuroscience-global-market-report

Diabetic Neuropathy Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/diabetic-neuropathy-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at [email protected]

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on: